A report details "deviations" during manufacturing of more than 135,000 packages, which could possibly contribute to other ...

Rybelsus is now FDA-approved for managing cardiovascular health. Doctors say oral GLP-1s may reduce heart attack and stroke ...

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular events.

The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, to reduce cardiovascular risk in type 2 diabetes patients. The drug can be prescribed to reduce major adverse cardiovascular ...

In combination, two commonly used heart drugs reverse fat accumulation in the liver, a study in animals has shown.

Semaglutide reduces cardiovascular events by 23% and direct heart disease death risk by 26% compared to dulaglutide in older ...

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded ...

A new experimental therapy helps restore the heart’s flexibility in models of stiffened heart failure. Michael Gotthardt and his colleagues at the Max Delbrück Center are working with U.S. researchers ...

The use of sacubitril/valsartan appears feasible and safe in recipients of left ventricular assist devices, reducing the need ...

Researchers found cardiovascular drugs were associated with 24.7 percent of all medication errors, followed by antibiotics at 19.1 percent, electrolytes at 11.3 percent, endocrine drugs at 8.8 percent ...

Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter, dragging the Swiss company's ...